138 related articles for article (PubMed ID: 17368906)
1. A cosmetovigilance survey in Europe.
Sautebin L
Pharmacol Res; 2007 May; 55(5):455-60. PubMed ID: 17368906
[TBL] [Abstract][Full Text] [Related]
2. Cosmetovigilance: definition, regulation and use "in practice".
Vigan M; Castelain F
Eur J Dermatol; 2014; 24(6):643-9. PubMed ID: 25672787
[TBL] [Abstract][Full Text] [Related]
3. Cosmetovigilance survey: are cosmetics considered safe by consumers?
Di Giovanni C; Arcoraci V; Gambardella L; Sautebin L
Pharmacol Res; 2006 Jan; 53(1):16-21. PubMed ID: 16183300
[TBL] [Abstract][Full Text] [Related]
4. [Cosmetovigilance: a French pharmacovigilance system for cosmetics developed by the French health products safety agency. A proposal for the future].
Tissier MH; Lepagnol F
Therapie; 2002; 57(3):273-82. PubMed ID: 12422542
[TBL] [Abstract][Full Text] [Related]
5. Understanding the adverse effects of cosmetics: a pilot project in cosmetovigilance.
Sautebin L
Drug Saf; 2008; 31(5):433-6. PubMed ID: 18422386
[TBL] [Abstract][Full Text] [Related]
6. Notification of undesirable effects of cosmetics and toiletries.
Sportiello L; Cammarota S; de Portu S; Sautebin L
Pharmacol Res; 2009 Feb; 59(2):101-6. PubMed ID: 19028583
[TBL] [Abstract][Full Text] [Related]
7. Vigilance in industry: cosmetics and household cleaning products. Balance sheet of case report from 2005 to 2007.
Kornfeld-Lecanu S; Zajaczkowski F; Dubourg S; Martin L; Lefort S; Siest S
Clin Exp Dermatol; 2010 Dec; 35(8):874-80. PubMed ID: 20718782
[TBL] [Abstract][Full Text] [Related]
8. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
9. Safety in Cosmetics and Cosmetovigilance, Current Regulations in Türkiye.
Altıokka İ; Üner M
Turk J Pharm Sci; 2022 Oct; 19(5):610-617. PubMed ID: 36317955
[TBL] [Abstract][Full Text] [Related]
10. Analysis and Reporting of Adverse Drug Reactions of Cosmetics at a Tertiary Care Hospital.
Paikray E; Bisoyi D; Rout A; Mishra V
Cureus; 2024 Mar; 16(3):e56856. PubMed ID: 38659521
[TBL] [Abstract][Full Text] [Related]
11. An observational study on adverse reactions of cosmetics: The need of practice the Cosmetovigilance system.
Lucca JM; Joseph R; Hussain Al Kubaish Z; Mohammad Al-Maskeen S; Ali Alokaili Z
Saudi Pharm J; 2020 Jun; 28(6):746-753. PubMed ID: 32550807
[TBL] [Abstract][Full Text] [Related]
12. Cosmetovigilance: the 'beautiful' risk.
Moretti U; Velo G
Drug Saf; 2008; 31(5):437-9. PubMed ID: 18422387
[TBL] [Abstract][Full Text] [Related]
13. Causality methods in cosmetovigilance: comparison of Colipa and PLM versus global introspection.
Zweers PG; Gilmour NJ; Hepburn PA; Gerritsen RF; van Puijenbroek EP
Regul Toxicol Pharmacol; 2012 Aug; 63(3):409-17. PubMed ID: 22609380
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of dermo-cosmetic products: a global cosmetovigilance system to optimise product development and consumer safety.
Ribet V; Albinet Claudin L; Brinio E; Berthier A; Millet V; Halbeher C; Sauvaire L; Laborderie M; Lafosse S; Olivan A; Giordano Labadie F; Ferret PJ
Eur J Dermatol; 2021 Aug; ():. PubMed ID: 34463281
[TBL] [Abstract][Full Text] [Related]
15. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
Lodén M; Ungerth L; Serup J
Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
[TBL] [Abstract][Full Text] [Related]
16. An Observational Study on Cosmetics Use-related Adverse Effects: Cosmetovigilance Need of the Day.
Mehta G; Tyagi DR; Sachdeva M; Tripathi R; Tyagi H
Drug Res (Stuttg); 2024 Apr; 74(4):164-170. PubMed ID: 38467158
[TBL] [Abstract][Full Text] [Related]
17. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe.
Nicoll A; Ammon A; Amato Gauci A; Ciancio B; Zucs P; Devaux I; Plata F; Mazick A; Mølbak K; Asikainen T; Kramarz P
Public Health; 2010 Jan; 124(1):14-23. PubMed ID: 20141821
[TBL] [Abstract][Full Text] [Related]
18. Cosmetovigilance in a tertiary care hospital: A prospective observational study.
Jyrwa S; Sebastian J; Shastry V
J Cosmet Dermatol; 2021 Mar; 20(3):804-811. PubMed ID: 32808451
[TBL] [Abstract][Full Text] [Related]
19. Reporting about disability evaluation in European countries.
Anner J; Kunz R; Boer Wd
Disabil Rehabil; 2014; 36(10):848-54. PubMed ID: 23919642
[TBL] [Abstract][Full Text] [Related]
20. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
